The Bio-Strategic Volatility Index: J&J, UnitedHealth & Eli Lilly

Executive Summary

Healthcare strategy has entered a high-volatility, telemetry-driven era where three companies—Johnson & Johnson, UnitedHealth Group, and Eli Lilly—are quietly rewriting how strategy is designed, monitored, and executed.

This Data Report introduces the Bio-Strategic Volatility Index (BSVI) for 2024–2026, quantifying how:

• GLP‑1 obesity drugs have turned Eli Lilly into a trillion‑dollar cardiometabolic powerhouse.
• Care model integration and risk-bearing platforms are reshaping UnitedHealth Group’s strategic leverage.
• Johnson & Johnson’s pivot to a pure-play Innovative Medicine and MedTech company is changing capital allocation and R&D telemetry.

For executives, the message is simple: annual plans cannot survive this level of strategic volatility. Healthcare leaders need a Strategy OS that turns drugs, claims, and patient flows into live telemetry—and that augments human judgment, rather than replacing it. This report provides the data backbone to make that shift.

---

Key Findings

• GLP‑1-driven strategic concentration: Eli Lilly’s obesity and diabetes franchise (Mounjaro, Zepbound, and related incretin therapies) now represents more than half of total revenue, with GLP‑1 products driving a ~45% year‑on‑year revenue increase to over $65B in 2025 and propelling market capitalization above $1 trillion, an unprecedented milestone in pharma.
• Strategic purification at J&J: After the Kenvue spin‑off, Johnson & Johnson has become a focused, two‑pillar healthcare company (Innovative Medicine and MedTech), targeting 5–7% operational annual revenue growth through 2030 and investing over $30B+ annually in R&D and M&A concentrated in oncology, immunology, neuroscience, and robotics.
• Care model telemetry at UnitedHealth: UnitedHealth Group’s combined insurance (UnitedHealthcare) and services (Optum) platforms have turned patient data, claims, and clinical workflows into a live risk engine—with care segmentation and vertically integrated delivery driving margin resilience despite macro volatility.
• Sector-wide volatility: Across biotech, healthcare, and pharma, earnings surprise ranges of ±10–20%, rapid label expansions, and accelerated FDA approvals have increased strategic "signal velocity"—a dynamic mirrored in other volatility indices like our Bio-Strategic Volatility Index article on Roche, Merck & J&J.
• Static strategy is value-destructive: Consulting research from sources such as Boston Consulting Group (BCG) and Harvard Business Review shows that organizations with continuous resource reallocation and short-cycle capital governance outperform static planners on TSR by up to 30–40% over a decade.
• IA beats full automation: Studies in MIT Sloan Management Review and Stanford Graduate School of Business highlight that AI-augmented decision systems outperform fully automated ones on complex, ambiguous choices—exactly the domain of healthcare strategy.

---

The Bio-Strategic Volatility Index (BSVI): 2024–2026

The Bio-Strategic Volatility Index measures how quickly and severely strategic variables in healthcare and pharma move across four dimensions:

1. Demand Volatility: Rapid shifts in patient volume, therapy adoption, and mix.
2. Regulatory Velocity: Speed and unpredictability of approvals, label changes, and reimbursement.
3. Capital Rotation: Changes in R&D spending, M&A focus, and divestitures.
4. Telemetry Maturity: Degree to which data flows are captured in real time and tied to decision-making.

Sector-Level Volatility Snapshot (Hypothetical Index)

The sector is simultaneously becoming more volatile and more measurable—creating a paradox: executives have more data and less time.

---

Eli Lilly: GLP‑1 Telemetry and Strategic Concentration

GLP‑1 as a Strategic Operating System

Eli Lilly’s rise is not just a product story—it is a strategic concentration story.

• Revenue concentration: Mounjaro (type 2 diabetes) and Zepbound (obesity) together represent over 50% of Lilly’s revenue, with total 2025 revenue around $65B, up roughly 45% year‑on‑year.
• Quarterly dominance: In a single quarter in 2026, Mounjaro and Zepbound generated ~$12.8B, around 65% of total revenue, signaling extreme product‑level concentration.
• Population penetration: Company executives have stated that Lilly is already serving roughly 10% of the U.S. obesity population with GLP‑1 therapies.
• Pipeline expansion: With oral GLP‑1s such as Foundayo gaining FDA approval, Lilly is deliberately building a portfolio of access modes (injectable, oral, once‑weekly, daily) to fit different patient segments.

From a Strategy OS perspective, Lilly is effectively treating cardiometabolic diseases as a dynamic telemetry layer:

• Real‑time prescription demand maps capacity constraints.
• Claims and outcome data feed into pricing, access, and label decisions.
• Manufacturing and supply chain are continuously recalibrated to avoid stockouts.

GLP‑1 Strategic Metrics Table

For executives, Lilly’s case shows that product telemetry can become the firm’s strategic heartbeat. Without a live telemetry system, a 10–20% swing in GLP‑1 demand or regulatory sentiment could destroy billions in value.

---

Johnson & Johnson: Strategic Purification and MedTech Volatility

From Conglomerate to Focused Healthcare Engine

Johnson & Johnson has executed one of the most significant strategic purification moves in modern healthcare:

• Consumer health spin‑off (Kenvue): J&J fully separated its consumer brands (Band‑Aid, Listerine, etc.), becoming a pure-play Innovative Medicine and MedTech company.
• Growth guidance: Post‑restructuring, J&J targets 5–7% annual operational revenue growth through 2030, focusing capital on high‑value disease areas.
• Portfolio focus: Pipeline investment is heavily concentrated in oncology, immunology, and neuroscience, while MedTech bets are placed on cardiovascular and robotics.
• R&D and M&A scale: In 2025, J&J invested an estimated $32B+ in R&D and M&A, including acquisitions in central nervous system (CNS) treatments and collaborations in in‑vivo CAR‑T.

This is not just restructuring; it is a telemetry re‑architecture:

• Fewer, more specialized business lines mean clearer signals and shorter lag between clinical data and capital decisions.
• MedTech telemetry (device utilization, surgical outcomes, real‑time diagnostics) can be wired into a Strategy OS to drive product roadmap decisions.

J&J Strategic Telemetry Table

J&J’s move illustrates a core Strategy OS principle: modular strategic frameworking. By decoupling consumer health and narrowing strategic scope, J&J has effectively modularized its strategy—reducing "strategic latency" and enabling more agile portfolio calibration.

For leaders exploring similar moves, our piece on Strategy OS for Automakers: From Static Plans to Adaptive Mobility offers a cross‑industry blueprint on how to modularize complex portfolios.

---

UnitedHealth Group: Care Model Volatility and Payer‑Provider Telemetry

While Eli Lilly and J&J showcase product and portfolio volatility, UnitedHealth Group demonstrates care model volatility:

• Dual-platform model: UnitedHealthcare (insurance) plus Optum (care delivery, analytics, pharmacy, and services) create a vertically integrated ecosystem where claims data, care pathways, and risk models continuously feed each other.
• Risk‑bearing care: Value‑based contracts and risk‑bearing provider groups move financial and clinical volatility inside UnitedHealth’s telemetry perimeter.
• Margin resilience: By controlling both premium flow and care cost levers, UnitedHealth can absorb shocks (e.g., GLP‑1 cost spikes, care deferrals) more effectively.

Though exact numbers vary, sector reports and consulting analyses (from sources like Deloitte, PwC, and Gartner) highlight several patterns:

• Vertically integrated payers tend to achieve 1–3 percentage points higher operating margins than non‑integrated peers in comparable segments.
• Organizations that embed real‑time analytics into claims adjudication and care management reduce avoidable utilization by 10–15%.

UnitedHealth Strategic Telemetry Table (Illustrative)

UnitedHealth’s system shows what Strategy OS in healthcare operations looks like: care models, contracts, and clinical outcomes wired into a telemetry engine that continuously adjusts risk, pricing, and intervention strategies.

---

Comparative Strategic Volatility: J&J vs Eli Lilly vs UnitedHealth

To make this index useful for executives, we translate strategic posture into a BSVI score (0–200) across four dimensions.

Bio-Strategic Volatility Index (BSVI) Comparison

Interpretation:

• Eli Lilly carries the highest demand volatility thanks to GLP‑1 demand sensitivity and payer dynamics, but also exhibits strong telemetry around drug performance.
• J&J shows elevated capital rotation volatility as it reweights into high‑risk, high‑reward therapeutic areas and MedTech bets.
• UnitedHealth exhibits the highest telemetry maturity, leveraging integrated data flows across payer and provider operations.

The BSVI framework surfaces a core strategic insight: volatility is not the enemy—it is unmeasured volatility that destroys value. Companies that combine high volatility with high telemetry maturity are more likely to translate turbulence into advantage.

---

Why Strategy Must Become Live: From Annual Plans to Micro-Options

Healthcare is now driven by micro‑shocks:

• An unexpected FDA label expansion for a GLP‑1 drug.
• A reimbursement change in a major market.
• A capacity constraint at a fill‑finish plant.
• A shift in employer benefit design.

Traditional strategy processes—annual plans, quarterly offsites, static roadmaps—cannot absorb shocks of this frequency and magnitude. Research in Harvard Business Review and MIT Sloan Management Review consistently shows that firms with dynamic resource allocation and shorter planning cycles outperform those with rigid annual budgeting.

enablegrowth’s core philosophy addresses this gap:

1. Intelligence-Augmented (IA): Strategy OS does not replace the strategist. Instead, it:

   • Captures locked human edits on assumptions, scenarios, and narratives.
   • Builds an institutional memory layer that stores past decisions and their outcomes.
   • Surfaces telemetry (drug performance, claims trends, care utilization) as context, not verdict.

2. Real-Time Telemetry: Static dashboards are not enough. Strategy OS must:

   • Consume live signals: prescribing data, claims adjudication, RWE, clinical trial updates.
   • Trigger automated staleness alerts when a strategic assumption (e.g., GLP‑1 demand curve, regulatory stance) is outdated.
   • Reframe strategy more like a live infrastructure—as discussed in The Live Infrastructure Advantage.

3. Perspective-Pivot Engine (PPE): Executive intelligence is perspective-dependent. Strategy OS must:

   • Recalibrate the strategic posture (Incumbent, Observer, Disruptor) based on user identity.
   • Shift the narrative tone from passive market observer to active Chief Strategy Officer.
   • Tailor every SWOT point and roadmap milestone to reflect the organization's unique competitive advantage.

That is also why the logic of a live strategy engine matters. A static plan cannot keep pace with a market where regulation, consumer adoption, and clinical cost structures shift in parallel.

The deeper point is that healthcare and biotech strategy is becoming an index of organizational adaptability. UnitedHealth’s strength is systemic integration. J&J’s strength is diversification. Eli Lilly’s strength is capacity scaling. Each is a response to the same reality: the industry now rewards companies that can sense, decide, and reallocate faster than their competitors.

If your organization is still managing strategy as a yearly ritual, it is already operating with structural delay. The next edge in healthcare will belong to teams that replace static plans with live calibration, build memory into execution, and turn volatility into a measurable advantage.

If you want to see how this thinking becomes an operating model, join the waitlist for Strategy OS →